



Pediatrics

Relationship of prenatal maternal obesity and diabetes to offspring neurodevelopmental and psychiatric disorders: a narrative review

Linghua Kong ^{1,2} · Xinxia Chen ^{1,2,3} · Mika Gissler^{4,5,6} · Catharina Lavebratt ^{1,2}

Received: 18 June 2019 / Revised: 20 April 2020 / Accepted: 20 May 2020
© The Author(s) 2020. This article is published with open access

Abstract

Obesity and diabetes is a worldwide public health problem among women of reproductive age. This narrative review highlights recent epidemiological studies regarding associations of maternal obesity and diabetes with neurodevelopmental and psychiatric disorders in offspring, and provides an overview of plausible underlying mechanisms and challenges for future human studies. A comprehensive search strategy selected terms that corresponded to the domains of interest (maternal obesity, different types of diabetes, offspring cognitive functions and neuropsychiatric disorders). The databases searched for articles published between January 2010 and April 2019 were PubMed, Web of Science and CINAHL. Evidence from epidemiological studies strongly suggests that maternal pre-pregnancy obesity is associated with increased risks for autism spectrum disorder, attention-deficit hyperactivity disorder and cognitive dysfunction with modest effect sizes, and that maternal diabetes is associated with the risk of the former two disorders. The influence of maternal obesity on other psychiatric disorders is less well studied, but there are reports of associations with increased risks for offspring depression, anxiety, schizophrenia and eating disorders, at modest effect sizes. It remains unclear whether these associations are due to intrauterine mechanisms or explained by confounding family-based sociodemographic, lifestyle and genetic factors. The plausible underlying mechanisms have been explored primarily in animal models, and are yet to be further investigated in human studies.

Introduction

Obesity among women of reproductive age increased globally from 2005 to 2014, although the rates varied widely between countries [1]. More than 30% of U.S. women aged 20–39 years were defined as obese

(BMI ≥ 30 kg/m²) in 2011–2014 [2]. The rise in the prevalence of obesity in this group is deemed as a major determinant of an increased risk of type 2 diabetes mellitus (T2DM) and gestational diabetes mellitus (GDM). Diabetes is characterized by elevated blood glucose levels, impaired insulin secretion, and/or peripheral resistance to insulin action. A systematic literature review reported in 2013 that worldwide up to 16.0% of women in reproductive age (20–49 years) were affected in pregnancy by diabetes, and the highest prevalence was found in the South-East Asia Region at 25.0% while in the North America and Caribbean Region the prevalence was 10.4% [3]. Around 87.5% of maternal diabetes cases are GDM, 7.5% are pre-pregnancy type 1 diabetes mellitus (T1DM), and 5% are T2DM [4]. Moreover, the prevalence of maternal diabetes is steadily increasing [5].

Maternal obesity has adverse effects on fetal outcomes, such as prematurity and congenital anomalies, as well as increases the risk for offspring adiposity, and disorders of offspring cardio-metabolism, respiration and cognition [6–9]. Besides, maternal obesity are reported to increase risks for offspring neuropsychiatric disorders, such as

✉ Catharina Lavebratt
catharina.lavebratt@ki.se

¹ Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden
² Center for Molecular Medicine, Karolinska University Hospital, Stockholm, Sweden
³ School of Nursing, Shandong University, Shandong, China
⁴ National Institute for Health and Welfare, Helsinki and Oulu, Oulu, Finland
⁵ Division of Family Medicine, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden
⁶ University of Turku, Research Centre for Child Psychiatry, Turku, Finland

Table 1 Human epidemiological studies examining effects of maternal obesity and diabetes on offspring neurodevelopmental and psychiatric disorders.

Offspring morbidity	Specific outcomes	Maternal exposures	Adjusted factors	Sample	Study design	Finding	Reference
Neuropsychiatric disorders	The diagnosis groups indicated by ICD-10 codes: F80 to F83, F84, F90 to F91, F92 to F95, F98, F20-F45, F50, and F51.	Pre-pregnancy BMI and PGDM	I:1,2,10,11 II:1,2,3,4,7,9,11,13	All live births in Finland between 2004 and 2014 (<i>n</i> = 649,043)	Cohort (Finland)	Maternal PGDM combined with severe maternal obesity markedly increased the risk of several children's psychiatric and mild neurodevelopmental disorders.	Kong et al. [12]
	The ADHD-DSM-IV form was completed by teachers. Cognitive and motor development tests were performed at the primary health center.	Pre-pregnancy BMI	I:1,2,5,7, 12 II:1,5,6,9,11 III:1,6	1827 Spanish children	Cohort (Spain)	Maternal obesity was associated with a reduction in offspring verbal scores at pre-school age.	Casas et al. [30]
	Children cognitive and psychomotor development were assessed at around age 14 months (range 11–22 months).	Pre-pregnancy BMI	I:2,4,5,12 II:1,3,4,5, 6,9 III:1,3,5,6	2644 mothers were recruited and 2226 children from four Spanish regions between 2004 and 2008	Cohort (Spain and Greece)	Maternal obesity was associated with reduced child cognitive development at early ages.	Casas et al. [44]
ASD	Children's mental and motor development were assessed by the Bayley Scales of Infant Development-II (BSID-II) and the Bayley Short Form-Research Edition (BSF-R) at age 2 years.	Pre-pregnancy BMI	I: 2,3,5 II:1,2,3,4, 5,6,9,10	6850 US children born in 2001	Cohort (USA)	An association was found between maternal BMI status and children's mental development but no association with children's motor development.	Hinkle et al. [45]
	ASD and other DDs were based on physician diagnoses as documented in electronic medical records.	Pre-pregnancy obesity, GDM	I:1,2,9 II:1,4,9	2734 children using a subset of the Boston Birth Cohort between 1998 and 2014	Cohort (USA)	Maternal obesity and maternal diabetes in combination were associated with increased risk for ASD and ID. ASD with ID may be etiologically distinct from ASD without ID.	Li et al. [15]
	ASD based on pediatric developmental specialist evaluations.	Pre-pregnancy BMI	I:1,2,3 II:1,3,4,5, 6,9,10,12, 13,14	322,323 singleton children born in 1995-2009 at Kaiser Permanente Southern California (KPSC) hospitals	Cohort (USA)	Exposure to maternal GDM diagnosed by 26 weeks' gestation was associated with risk of ASD in offspring.	Xiang et al. [14]
	ASD diagnosis using ICD-9, ICD-10, and DSM-IV codes.	Pre-pregnancy BMI, GWG	I:1,2,11 II:1,3,6,11 III:3,5,7	333,057 individuals born 1984–2007, of whom 6,420 with ASD	Cohort (Sweden)	Maternal BMI was associated with ASD. Sibling analyses and paternal BMI analyses indicated that maternal BMI may also be a proxy marker for other familial risk factors.	Gardner et al. [28]

Table 1 (continued)

Offspring morbidity	Specific outcomes	Maternal exposures	Adjusted factors	Sample	Study design	Finding	Reference
	ASD diagnostic from test and interview results and from information collected from parents and teachers.	Pre-pregnancy BMI	I:1 II:5,9 III:1	92,909 children born from 1999 to 2009	Cohort (Norway)	Both maternal and paternal obesity were associated with an increased risk of ASD in offspring.	Surén et al. [29]
	ASD diagnosis identified by trained clinicians.	Maternal diabetes, hypertension, and obesity during pregnancy	I:1,2,4 II:1,3,5, III:1,3,5,7	Children aged 2 to 5 years (517 ASD, 172 DD, and 315 controls)	Case-control study (USA)	Diabetes, hypertension, and obesity were more common among mothers of children with ASD compared with controls. Diabetes, in particular, was associated with statistically significantly greater deficits in expressive language among children with ASD.	Krakowiak et al. [27]
	ASD identified by questionnaire and parental report.	GDM	I:8 II:1,2,3,6, 8,9,13 III:1,5	116,608 female nurses aged 25–42 years when recruited in 1989	Cohort (USA)	GDM was associated with an increased risk of ASD in offspring.	Lyall et al. [32]
	ASD diagnosis identified using ICD-9 code 299 or ICD-10 code F84.	Pre-pregnancy weight and GWG	I:1,2,5,13 II:7,10,11	129,733 children born between 1990 and 2002	Cohort (Canada)	Maternal weight of 90 kg or more and weight gain of 18 kg or more were both independent risk factors for ASD.	Dodds et al. [33]
ADHD	ADHD cases were identified based on ICD-9 codes 314 or refills of ADHD-specific medications during the follow-up window from at least two separate visits.	T1DM, T2DM, GDM	I:1,2,11 II:1,3,5,6, 9,11,13	333,182 singletons born in 1995–2012	Cohort (USA)	Compared with children unexposed to diabetes, the adjusted HRs for ADHD in children were 1.57 (95% CI 1.09–2.25) for exposure to T1DM, 1.43 (1.29–1.60) for T2DM, 1.26 (1.14–1.41) for GDM requiring antidiabetic medications, and 0.93 (0.86–1.01) for GDM not requiring medications.	Xiang et al. [13]
	Individuals with ADHD were identified according to ICD-9 code 314 and ICD-10 code F90.	T1DM	I:1,2,6,10 II:1,4,5,6, 11,13 III:1,3,5,7	15,615 individuals were born after parental diagnosis of T1DM, and 1,380,829 children with parents without a diagnosis of T1DM were matched control subjects	Cohort (Sweden)	In this retrospective cohort study, we found that a parental history of T1D was associated with a 29% increased risk of being diagnosed with ADHD.	Ji et al. [40]
	ADHD diagnosis (ICD-10 codes F90.0, F90.1, or F98.8) and ASD diagnosis	Pre-pregnancy BMI	I:3 II:1,4,6,11,14 III:5	81,892 children of whom 2417 (3.0%) had an ADHD diagnosis, and 1118 (1.4%)	Cohort (Denmark)	An association was found between maternal overweight and increased risk of ADHD.	Andersen et al. [170]

Table 1 (continued)

Offspring morbidity	Specific outcomes	Maternal exposures	Adjusted factors	Sample	Study design	Finding	Reference
	(ICD-10 code F84.0, F84.1, F84.5, F84.8, or F84.9).			had an ASD diagnosis while 606 children (0.7%) had both disorders		With regard to ASD, there was an elevated risk of ASD in children with underweight or obese mothers.	
	ADHD diagnosis (ICD-10 codes F90 + F98.8).	Auto-immune diseases including T1DM	I:1,2 II:11 III:7	All children born in Denmark from 1990 to 2007 ($N = 983,680$).	Cohort (Denmark)	A personal history and a maternal history of autoimmune disease were associated with an increased risk of ADHD. The previously reported association between T1DM and ADHD was confirmed.	Nielsen et al. [39]
	ADHD diagnosis (ICD-9 codes 314.00 or 314.01) at age 5–12 years.	Pre-pregnancy BMI	I:1,2,11 II:1,10,11,14	4682 ($N = 187$ with ADHD) children born to 3645 different mothers.	Sibling-comparison design (USA)	The association between maternal pre-pregnancy BMI and offspring ADHD may be better accounted for by familial or maternal confounds rather than by a direct effect of maternal BMI.	Musser et al. [37]
	The dispensed and reimbursed ADHD medications methylphenidate (ATC code N06BA04), atomoxetine (ATC code N06BA09), and racemic amphetamine (ATC code N06BA01).	Inflammatory and immune system diseases (T1DM, T2DM, hypertension)	I:1,3 II:1,2,5,9,12,14 III: 8	All individuals ($N = 2,322,657$) born during the period 1967–2008	Register-based case-control study (Denmark)	T1DM was associated with ADHD in offspring. In contrast, chronic hypertension and T2DM were not associated with ADHD.	Instanes et al. [38]
	Hyperkinetic disorder diagnoses (ICD-9: 314; DSM-IV-TR: 314; ICD-10: F90); or treated with ADHD medication at age 3 years.	Pre-pregnancy BMI	I:1,2,11 II:1,3,4,5, 15	673,632 individuals born in Sweden between 1992 and 2000	Cohort (Sweden)	At the population level, maternal overweight and obesity were associated with increased risk of offspring ADHD. In full sibling comparisons, however, previously observed associations no longer remained.	Chen et al. [36]
	ADHD diagnosis rated using DSM-IV.	GDM	I:1,2,3,4 II:1,4,11 III:7	$N = 212$; 3 and 4-year-old children in preschools	Cohort (USA)	GDM and low socioeconomic status, especially in combination, heighten the risk for childhood ADHD.	Nomura et al. [11]
					Cohort (USA)		

Table 1 (continued)

Offspring morbidity	Specific outcomes	Maternal exposures	Adjusted factors	Sample	Study design	Finding	Reference
	School Entry Assessment (SEA) results (age 4 years), and IQ (age 8 years), and General Certificate of Secondary Education (GCSE) results (age 16 years).	GDM, preexisting diabetes	I:2,5 II:1,4,5,6,7,9,10,14	8515 women from the Avon Longitudinal Study of Parents and Children (ALSPAC) delivered between 1991 and 1992		Maternal diabetes in pregnancy was associated with lower offspring cognition and educational attainment.	Fraser et al. [51]
	Cognitive function assessed by Raven's Standard Progressive Matrices and three verbal subtests (information, similarities and vocabulary) from the Wechsler Adult Intelligence Scale (WAIS)	T1DM	I:1,2,3 II:1,4,5,6,9,13,14 III:1,3	Adult offspring of women with Type 1 diabetes ($n = 158$) and a reference group from the background population ($n = 118$)	Cohort (Denmark)	Impaired cognitive function in adult offspring of women with T1DM. Harmful effects of maternal hyperglycemia may be mediated through delivery at <34 weeks.	Clausen et al. [54]
	Children's cognition and behavior was assessed by parents.	Pre-pregnancy BMI	II:4,5,6 III:1,3	British ALSPAC ($N = 5000$) and Dutch Generation R ($N = 2500$) cohorts	Cohort (UK and Netherlands)	Little consistent evidence of intrauterine effects of maternal overweight on child cognition and behavior.	Brion et al. [48]
	Cognitive function assessment using tests from the Kaufman Assessment Battery for children-second edition and additional tests measuring learning, long-term storage/retrieval, short-term memory, reasoning, attention and concentration, visio-spatial and verbal abilities.	GDM	I:1,2,3 II:1,3,5,6,9,10 III:1,3	515 healthy children (32-offspring of mothers with GDM; 483 offspring of non-GDM mothers (controls) from the Mysore Parthenon birth cohort	Cohort (India)	There was no evidence of lower offspring cognitive ability for mothers with GDM.	Veena et al. [52]
Affective disorders	Affective problems were assessed using the CBCL/4–18 according to DSM-IV.	Pre-pregnancy BMI	I:3,5 II:1,4,5,6,13,14,15 III:3,6	2868 live-born children in the 17-year follow-up since 1989	Cohort (Australia)	Overweight or obesity were associated with increased risks for affective problems during childhood and adolescence.	Robinson et al. [56]
Psychosis and schizophrenia	Non-affective psychoses was assessed by ICD-10: F20-F29; ICD-9 codes 295, 297 and 298, except 298A and 298B; and narrowly defined schizophrenia (ICD-9 code 295 and ICD-10 code F20).	Pre-pregnancy BMI, GWG	I:1,2,11 II:1,3,6,11 III:3,4,5,7	Follow-up 526,042 children born between 1982 and 1989	Cohort (Sweden)	A weak U-shaped association between maternal BMI at the beginning of pregnancy and the increased risk for non-affective psychosis in offspring. No association was apparent between elevated maternal BMI and schizophrenia risk.	Mackay et al. [58]

Table 1 (continued)

Offspring morbidity	Specific outcomes	Maternal exposures	Adjusted factors	Sample	Study design	Finding	Reference
Eating Disorders	Diagnosis of eating disorder (anorexia, bulimia, and binge-eating disorder) by DSM-IV or DSM-V criteria.	Pre-pregnancy BMI	No adjusted factors	N = 1383; population-based sample of male and female adolescents followed from ages 14–20 years	Cohort (Australia)	Each one-unit increase in maternal early pregnancy BMI increased odds of eating disorders in offspring by 10%.	Allen et al. [59]

I. Child factors: 1 = birth year, 2 = birth sex, 3 = birth weight (BMI or child's weight and head circumference at birth), 4 = race/ethnicity, 5 = breastfeeding duration, 6 = low Apgar score, 7 = child physical activity, 8 = twin births, 9 = preterm birth, 10 = small for gestational age, 11 = birth order, 12 = nursery attendance and/or main childminder, 13 = sibling with neuropsychiatric disorders.

II. Maternal factors: 1 = age at delivery, 2 = marital status, 3 = race/ethnicity, 4 = smoking and/or alcohol use, 5 = education, 6 = socioeconomic status, 7 = mode of delivery, 8 = miscarriages or induced abortion, 9 = parity, 10 = weight (BMI, gestational weight gain), 11 = psychiatric disorder and/or neurological illness and/or major CNS anomaly and/or intelligence, 12 = use of psychotropic medicine, 13 = pregnancy complications or comorbidity (including gestational diabetes and/or hypertensive diseases and/or systemic inflammatory disease and/or pulmonary disease, heart disease, renal disease, anemia as well as other conditions), 14 = gestational age at delivery, 15 = cohabitation with child's father at childbirth.

III. Paternal factors: 1 = education, 2 = smoking, 3 = socioeconomic status, 4 = race/ethnicity, 5 = age at time of birth, 6 = BMI, 7 = history of psychiatric disorders, 8 = use of psychotropic medicine.

ASD autism spectrum disorder, ADHD attention deficit hyperactivity disorder, BMI body mass index, DDs developmental disorders, DSM the diagnostic and statistical manual of mental disorders, GWG gestational weight gain, GDM gestational diabetes, ICD international statistical classification of diseases and related health problems, IQ intelligence quotient, PGDM pre-gestational diabetes, T1DM type 1 diabetes, T2DM type 2 diabetes.

autism spectrum disorder (ASD), attention deficit hyperactivity disorder (ADHD), anxiety and depression, schizophrenia and other neuropsychiatric disorders [10] (Table 1). While the association between maternal obesity and offspring neuropsychiatric disorder has been extensively studied, especially for ASD, the influence of maternal diabetes on offspring neuropsychiatric disorders, other than ASD and ADHD [11–16], is less well explored. Likewise, little is known regarding the size of the joint effects of maternal pre-pregnancy obesity and different types of maternal diabetes on neuropsychiatric outcomes in offspring [12]. Maternal obesity is highly comorbid with T2DM and GDM [17], and proposed mechanisms of their associations with offspring neuropsychiatric disorders overlap between obesity and diabetes [18].

Studies where the outcomes are compared between siblings discordant for the exposure can enable control of unmeasurable familial confounding as they intrinsically control for maternal genetic factors and environmental exposures that have remained constant or comparable across pregnancies. However, this study design is less applicable where exposure-discordant siblings are scarce, e.g., for exposure being maternal T1DM.

Because of the increasing numbers of pregnant mothers with obesity and/or diabetes, and available preventive and treatments opportunities, it is important to identify the relationship between gestational environment and offspring neuropsychiatric disorders. In this review, we aimed to narratively describe the reported findings about associations of maternal pre-pregnancy obesity and diabetes with offspring neuropsychiatric disorders, and to provide an overview of the plausible underlying mechanisms, as well as challenges for future research.

Data sources and search strategies

The databases including Web of Science, PubMed and CINAHL were comprehensively searched by using combinations of key words that corresponded to the domains of interest: “offspring OR child*” AND “cognitive development OR cognitive functions OR neurodevelopmental disorders OR neuropsychiatric disorders OR mental health OR psychiatric disorders OR brain development OR ASD OR autism spectrum disorder OR ADHD OR attention-deficit hyperactivity disorder OR schizophrenia OR psychosis OR affective disorder OR behavioral disorders OR intelligence disability OR IQ” AND “mother* OR pregnan* OR women of reproductive age” AND “maternal obesity OR maternal BMI OR Body Mass Index OR adiposity OR overweight OR obesity” AND “type 1 diabetes OR type 2 diabetes OR gestational diabetes OR diabetes insipidus OR diabetes mellitus OR DM OR diabetes”. The publication period

interval was from January 1, 2010 to April 1, 2019. This is a narrative review as opposed to a systematic review, which is one of its limitations.

Autism spectrum disorder (ASD)

Maternal pre-pregnancy obesity and the risk for offspring ASD

ASD is characterized by developmental delays, communication difficulties, deficits in social functioning, and stereotyped, restricted and repetitive behaviors (American Psychiatric Association, APA) [19]. The association between maternal obesity and offspring ASD has been extensively reviewed confirming an increased risk of ASD in offspring of obese mothers [20–22].

A systematic review and meta-analysis involving 943,293 children and 30,337 cases searched up to March 2018 found that both maternal obesity (OR = 1.41, 95% CI = 1.19–1.67) and maternal overweight (OR = 1.16, 95% CI = 1.05–1.27) were significantly associated with ASD in offspring [23]. Similarly, another meta-analysis including 509,167 participants and 8403 diagnosed cases reported that maternal overweight and obesity was found to have 28 and 36% higher risk for ASD than normal weight during pre-pregnancy or pregnancy [24]. These results are consistent with the other meta-analysis studies [25, 26].

The largest nationwide cohort study including 649,043 births between 2004 and 2014 in Finland showed that obese mothers had 28% increased risk of having a child with ASD compared with mothers with a normal BMI after adjusting for potential confounders (HR = 1.28, 95% CI = 1.06–1.55) [12]. Also, a population-based, case-control study including 1004 children aged 2–5 years in California, USA between 2003 and 2010 showed that mothers with obesity were 60% more likely to have a child with ASD (95% CI = 1.10–2.37) [27]. Moreover, a Swedish population-based cohort study including 333,057 participants born 1984–2007 showed that both maternal and paternal obesity were associated with increased risk of ASD in offspring (OR_{maternal} = 1.94, 95% CI = 1.72–2.17; OR_{paternal} = 1.47, 95% CI = 1.12–1.92) [28].

However, a population-based, prospective Norwegian cohort study including 92,909 children born from 1999 to 2009 did not replicate the maternal obesity-offspring ASD association (OR = 1.09, 95% CI = 0.74–1.59) [29]. Further, the association between maternal obesity and the risk of ASD was not supported by a study using sibling-comparisons [28], which indicated that maternal BMI may be a proxy indicator for familial risk factors such as socio-economic status (SES) and genetic background [28, 30]. However, the aforementioned studies reporting

positive association were adjusting for various potential familial factors suggesting that obesity-associated intrauterine environment explains at least some of the maternal obesity-offspring ASD association.

Maternal diabetes and the risk for offspring ASD

Maternal diabetes was found to be positively associated with ASD risk in offspring, based primarily on studies of GDM. A systematic review and meta-analysis published in 2018 involving 16 studies reported that GDM was associated with ASD in children (RR = 1.48, 95% CI = 1.26–1.75) [16]. Another meta-analysis of mothers with diabetes before or during pregnancy, i.e., not only GDM, involving 12 studies also demonstrated an increased risk of ASD in offspring. The pooled RR was 1.72 (95% CI = 1.24–2.41) among case-control studies, and 1.48 (95% CI = 1.25–1.75) among cohort studies [31].

A large, multiethnic clinical longitudinal cohort study in California including 322,323 singletons born in 1995–2009 showed that the ASD risk in offspring after adjusting for potential confounders was associated with both maternal GDM diagnosed by the 26th gestational week (HR = 1.42, 95% CI = 1.34–2.32) and maternal preexisting T2DM (HR = 1.33, 95% CI = 1.07–1.66) [14]. Similarly, in a prospective national cohort study including 66,445 pregnancies in the USA, GDM was found to be associated with increased risk of ASD (OR = 1.76, 95% CI = 1.34–2.32) [32].

However, the results from other studies investigating the association between diabetes and offspring ASD have been conflicting. For example, a large Finnish nationwide cohort study including 649,043 newborns between 2004 and 2014 did not find any clear effects of neither GDM nor PGDM on ASD risk in normal-weight mothers (OR_{GDM} = 1.06, 95% CI = 0.88–1.28; OR_{PGDM} = 0.54, 95% CI = 0.20–1.44) [12]. Another retrospective longitudinal cohort study including all live births (129,733 births) among residents in a Canadian province between 1990 and 2002 found that neither diabetes before the onset of pregnancy nor GDM was associated with ASD (OR_{DM} = 1.98, 95% CI = 0.94–4.16; OR_{GDM} = 1.29, 95% CI = 0.90–1.83) [33]. The discrepancy between findings could possibly be influenced by different BMI profiles between different cohorts in mothers with T2DM or GDM and in mothers without diabetes.

Maternal pre-pregnancy obesity and diabetes in combination and the risk for ASD

The joint effect size between maternal obesity and diabetes on offspring ASD has been reported to be larger than that of obesity or diabetes alone. The Boston birth cohort study

between 1998 and 2014 among 2734 children reported three-fold increased risks for ASD of maternal pre-pregnancy obesity and pre-gestational diabetes (PGDM) in combination (HR = 3.91; 95% CI = 1.76–8.68), as well as maternal obesity and GDM in combination (HR = 3.04; 95% CI = 1.21–7.63) [15]. Recently, a Finnish population-based cohort study consisting of 649,043 participants born between 2004 and 2014 showed that ASD risk in offspring was three- to six-fold increased for mothers with insulin-treated PGDM and obesity (HR = 3.64; 95% CI = 1.63–8.16), as well as for mothers with insulin-treated PGDM combined with severe obesity (HR = 6.49; 95% CI = 3.08–13.69) compared to normal-weight nondiabetic mothers [12]. The corresponding joint effects of GDM with obesity and severe obesity were HR = 1.56 (95% CI = 1.26–1.93) and HR = 1.37 (95% CI = 1.04–1.81), respectively [12].

Attention-deficit/hyperactivity disorder (ADHD)

Maternal pre-pregnancy obesity and the risk for offspring ADHD

ADHD is marked by an inattention and/or hyperactivity-impulsivity that interferes with functioning or development. The impact of maternal obesity on offspring ADHD has been reviewed in the past five years. For example, a systematic review and meta-analysis including 41 studies published before April 2017 indicated that maternal pre-pregnancy obesity increased the risk of ADHD in offspring (OR = 1.62, 95% CI = 1.23–2.14) [25].

Recently, a large, population-based nationwide cohort study in Finland consisting of 649,043 births between 2004 and 2014 reported that maternal pre-pregnancy obesity was associated with offspring ADHD after adjusting for potential confounders (OR = 1.44, 95% CI = 1.28–1.63) [12]. Further, a prospective pregnancy cohort from Sweden, Denmark and Finland involving 12,556 school-aged children indicated that obese mothers had an approximately doubled risk of ADHD in offspring (OR = 1.89, 95% CI = 1.13–3.15) [34]. Besides, a longitudinal study reported that maternal pre-pregnancy BMI played a predictive role in the poorer psychosocial development, as evidenced by lower social competence and higher externalizing symptoms in offspring [35].

Additionally, a large population-based cohort study of 673,632 children born in Sweden between 1992 and 2000 showed that maternal obesity was associated with an increased risk of offspring ADHD (HR = 1.64, 95% CI = 1.57–1.73) after adjustment for measured covariates. In full-sibling comparisons of the same cohort, however, the

associations no longer remained (HR = 1.15, 95% CI = 0.85–1.56) [36]. Similarly, another population-based sibling-comparison study consisting of 4682 children in the upper Midwest of the USA between 1995 and 2013 found no statistically significant association between maternal obesity and ADHD risk among siblings, although one unit higher BMI increased the risk of offspring ADHD by 4.2% (95% CI = 1.02–1.06) at maternal level [37]. The two sibling-comparison studies suggested that besides the major exposures of interest, other unmeasured familial lifestyle-related characteristics associated with obesity and ADHD may explain part of the maternal obesity–offspring ADHD associations detected [7]. Hence, similar to the case for maternal obesity–offspring ASD association, the sibling analyses do not support an intrauterine environmental causality, however the rigorous adjustments in the other studies for various potential familial factors support some degree of involvement of an obesity-associated intrauterine environment.

Maternal diabetes and the risk for ADHD

Studies have explored the relationship of both maternal GDM and maternal pre-pregnancy diabetes to the risk of offspring ADHD. A longitudinal cohort study including 212 preschool children with ADHD in New York found that GDM was associated with an over 2-fold increased risk for ADHD (OR = 2.20; 95% CI = 1.00–4.82) in offspring at age 6 years compared with those unexposed [11]. A large population-based cohort study including 649,043 births in Finland between 2004 and 2014 studied normal-weight mothers and found smaller effects of GDM on offspring ADHD risk (HR = 1.15; 95% CI = 1.01–1.30) [12]. Moreover, a retrospective birth cohort study including 333,182 singletons born in 1995–2012 within Kaiser Permanente Southern California hospitals found that the adjusted HRs for offspring ADHD were 1.26 (95% CI = 1.14–1.41) for GDM requiring antidiabetic medication, and 0.93 (95% CI = 0.86–1.01) for GDM not requiring antidiabetic medication, compared with children unexposed in utero to diabetes [13]. Exposure to T1DM had an adjusted HRs for ADHD in children at 1.57 (95% CI = 1.09–2.25), and 1.43 (95% CI = 1.29–1.60) for T2DM [13]. Further, a longitudinal nationwide register-based cohort study involving 2,274,713 in Norway from 1967 to 2012 reported that pre-pregnancy T1DM was associated with an increased risk for ADHD in offspring after adjusting for potential confounders (OR = 1.6; 95% CI = 1.3–2.0), while exposure to maternal T2DM was not associated with offspring ADHD risk (OR = 1.1; 95% CI = 0.7–1.8) [38].

Similarly, maternal pre-pregnancy T1DM was associated with an increased risk of offspring ADHD (RR = 1.31, 95% CI = 1.03–1.63) in a large register-based cohort study

including 983,680 individuals born in Denmark from 1990 to 2007 [39], and in a retrospective cohort study involving 15,615 individuals born in Sweden between 1970 and 2012 (HR 1.35; 95% CI = 1.18–1.55) [40].

Overall, there is support for that exposure to maternal T1DM increases the offspring risk of ADHD modestly. The influence of GDM or T2DM on offspring ADHD risk is less clear. Various maternal and birth factors were adjusted for in aforementioned studies, again proposing some involvement of intrauterine environment, however, sibling pair analyses have not been reported. For T1DM, sibling pair analysis would require very large populations as exposure-discordant siblings are rare.

Maternal pre-pregnancy obesity and diabetes in combination and the risk for offspring ADHD

Only few studies have considered the combined effects of maternal obesity and diabetes on the risk of ADHD in offspring. Among the two studies on this topic, a prospective birth cohort study including 2,734 mother-child pairs at the Boston Medical Center from 1998 to 2014 reported that there was no association with offspring ADHD, neither for maternal pre-pregnancy obesity–GDM (HR = 1.20, 95% CI = 0.49–2.93), nor for maternal pre-pregnancy obesity–PGDM (HR = 1.06, 95% CI = 0.34–3.36) [15]. Similarly, another population-based nationwide cohort study including 649,043 births in Finland between 2004 and 2014 found no combined association of maternal obesity and insulin-treated PGDM with risk for offspring ADHD compared to normal-weight mothers without PGDM (HR = 1.00, 95% CI = 0.32–3.10) [12]. This study, however, found a markedly higher risk for ADHD for offspring of severely obese mothers with insulin-treated PGDM (HR = 6.03, 95% CI = 3.23–11.24; HR_{no diabetes, severe obesity} = 1.88, 95% CI = 1.58–2.23). This study also indicated that the joint effect of maternal GDM combined with obesity, or severe obesity, increased the risk for offspring ADHD (HR_{GDM, obesity} = 1.64, 95% CI = 1.42–1.88) compared with that of mothers with only obesity (HR_{no diabetes, obesity} = 1.44, 95% CI = 1.28–1.63) [12].

Cognitive function and intellectual ability

Maternal pre-pregnancy obesity and the risk for offspring cognitive and intellectual function

The impact of maternal obesity on cognitive function and intelligence development in the offspring has been reviewed [10, 20, 22, 41]. A meta-analysis published in 2018 representing 36 cohorts indicated that maternal pre-pregnancy overweight or obesity was associated with increased risk of

offspring developmental delay (OR = 1.58, 95% CI = 1.39–1.79) and emotional/behavioral problems (OR = 1.42; 95% CI = 1.26–1.59) [25]. An increasing number of longitudinal, prospective, and observational studies have explored the association between maternal pre-pregnancy BMI and cognitive performance in the offspring [42–48]. Among these previous studies, most studies suggested that maternal pre-pregnancy obesity was associated with low IQ, including poorer motor, spatial, and verbal skills. [42–45, 48–50] Also a prospective population based cohort of 19,517 children at 5 and 7 years of age in the United Kingdom showed that maternal pre-pregnancy BMI was negatively associated with children's cognitive performance. The relationship appeared to become stronger as children got older, although the overall effect size was modest [42]. To address potential paternal confounding, a few studies considered not only maternal but also paternal BMI [43, 44, 48]. Wherein, a Danish national birth cohort study including 1783 mothers reported that increased maternal and paternal pre-pregnancy BMI were associated with lower offspring IQ at similar effect sizes after adjusting for potential confounders, suggesting that not only the intrauterine environment was involved [43]. However, findings from two southern European birth cohort studies from Spain and Greece found that maternal BMI effect estimates on infant cognitive development were greater than those of paternal BMI [44], which was consistent with mainly maternal-specific or intrauterine effects. Moreover, one study including two cohorts, one British ($N = 5000$) and the other Dutch ($N = 2500$), showed that neither maternal nor paternal pre-pregnancy overweight were consistently associated with child cognitive abilities [48]. Thus, when interpreting the findings potential unidentified genetic and familial confounding factors and ongoing brain maturation to early adulthood should be considered.

Maternal diabetes and the risk for offspring cognitive and intellectual function

Maternal PGDM and GDM have been studied as potential factors impairing cognitive function in childhood [51–54]. In particular, a systematic review and meta-analysis including 12 studies and 6140 infants assessed the cognitive abilities in children (up to 14 years) of diabetic and non-diabetic mothers, and found no significant difference [55]. A large family-based prospective cohort study ($N = 664,871$ from 543,203 families) linking nation-wide registers in Sweden reported that maternal GDM was associated with lower educational achievement and IQ scores among men at 16–18 years after adjustment for potential confounders including also maternal pre-pregnancy BMI, while there was no such association within siblings [53]. Thus, this association was likely due to common shared familial characteristics such as familial socioeconomic position,

known to influence both educational attainment and GDM, rather than intrauterine mechanism [53].

Depression, anxiety, psychosis and eating disorders

Depression is characterized by a depressed mood, loss of interest and a feeling of worthlessness, whereas anxiety is characterized by worried thoughts, fear and associated physical symptoms. Only few human studies have investigated if maternal obesity is associated with offspring mood or anxiety disorders, and for maternal diabetes exposure no report on offspring mood and anxiety disorders was found. A population-based cohort study from the Western Australian Pregnancy Cohort including 2,868 live births followed 17 years indicated that maternal pre-pregnancy obesity was associated with childhood affective problems including depression and anxiety (OR = 1.72, 95% CI = 1.11–2.67) [56].


Psychosis is a dissociation from reality based on irregular thoughts and changes of cognitive function. A qualitative review including four studies with 305 cases of schizophrenia and 24,442 controls showed that maternal pre-pregnancy obesity was associated with 2- to 3-fold increased risk of schizophrenia in offspring, although maternal schizophrenia and hence possible genetic confounding was not taken into account [57]. A population-based cohort study of 526,042 individuals born in Sweden between 1982 and 1989 reported a weak U-shaped association between maternal early-pregnancy BMI and the risk for non-affective psychosis in offspring, and the matched-

sibling analyses found no association between maternal overweight (HR = 1.11, 95% CI = 0.73–1.68) or obesity (HR = 0.56, 95% CI = 0.23–1.38) and risk for non-affective psychosis in offspring [58]. Eating disorders include anorexia, bulimia and binge-eating disorder. A population-based Australian pregnancy cohort study including 1,383 offspring followed prospectively from 14 to 20 years of age found that maternal early-pregnancy BMI associated positively with the risk of eating disorders in offspring (OR = 1.10, 95% CI = 1.05–1.15) [59].

Brief overview of potential pathways and mechanisms

Confounded by parental genetic and familial postnatal environmental factors, it is challenging to explore underlying mechanisms explaining the putative associations between maternal obesity/diabetes and offspring neurodevelopmental and psychiatric disorders. However, animal models can provide putative causal links between exposure to maternal obesity/diabetes and some behavioral symptoms or functionalities associated with human neurodevelopmental and psychiatric disorders in offspring (Fig. 1). Rodent models on high fat diet (HFD) or with hyperglycemia have been used in this context supporting a role of the intrauterine environment [20, 60–63]. Offspring to pregnant dams of these models display altered behaviors such as hyperactivity, reduced sociability and anxious and depressive-like behaviors [20]. The potential underlying mechanisms between prenatal HFD exposure and offspring neurodevelopment have been reviewed previously [64].

Fig. 1 Pathways linking maternal obesity and diabetes with potential neurodevelopmental and psychiatric disorders in offspring. Genetic inheritance, pre-pregnancy and pregnancy effects of a metabolically dysregulated environment, and postnatal effects of psychosocial stress, malnutrition and the microbiota are illustrated.



Here, we give a brief overview of the putative key mechanisms of how model and human maternal obesity and diabetes can influence offspring neurodevelopment.

During the human pregnancy, insulin resistance is gradually elevated to ensure adequate nutrition for the fetus. Thus, postprandial glucose levels, basal and stimulated insulin secretion, and hepatic glucose production are elevated. An obese and/or diabetic state can exacerbate the normal pregnancy-related metabolic changes. Insulin resistance, hyperinsulinemia, elevated plasma leptin levels and low-grade inflammation are commonly seen in obese and/or diabetic pregnant mothers [65–69], also in a non-pregnant severely obese women [70]. These metabolic and inflammatory states affect the placenta and thereby influence the exchange of nutrients between the mother and the fetus. Thus, these states leads to increased placental transfer of glucose and fatty acids, placental inflammatory cytokine release and influences the placenta's production of hormones and growth factors that are crucial for embryonic development [71–74]. The elevated levels of glucose, fatty acids, leptin, inflammatory cytokines and chemokines also directly expose the fetus as these molecules can pass the placenta [75]. Consequently and importantly, fetal secretion of insulin is increased in response to elevated glucose levels passed over from the mother, and so is fetal insulin resistance [76]. Exposure of the fetus to maternal obesity and diabetes has in rodent models been suggested to have long-lasting effects on organ development and function, including also neuroendocrine regulation and brain development [64], through hyperglycemia [77], oxidative stress [78, 79], lipotoxicity [80, 81], inflammation [82–84] and the associated hormones insulin and leptin [20, 66, 85]. The long-lasting effects can also be mediated by epigenetic modifications.

Metabolic hormones

As aforementioned, insulin resistance is gradually elevated during pregnancy causing increased plasma insulin levels. An obese and/or diabetic state can exacerbate these pregnancy-induced changes in maternal insulin levels as insulin resistance, hyperinsulinemia and low-grade inflammation are commonly seen in these states [70]. Inflammation, often initiated in white adipose tissue of obese subjects, is known to induce insulin resistance by inhibiting insulin receptor signaling [86]. Insulin resistance in GDM is associated with elevated levels of TNF- α and pro-inflammatory cytokines during pregnancy [87]. Insulin does not pass the placenta, but glucose do, so the fetus becomes exposed to the maternal glycemic state, and in the event of hyperglycemia or fetal insulin resistance it secretes more fetal insulin. Moreover, insulin is an important growth

factor in brain development [88]. Increased peripheral insulin levels results in insulin resistance which itself has large effects on the brain and have been associated with depression [89–92].

Leptin is mainly produced by adipose tissue, and leptin receptors are widely distributed in the central nervous system [93]. Leptin resistance is common in an obese state, one potential mechanism being reduced leptin transport across the blood-brain barrier due to elevated levels of triglycerides. Hence, plasma leptin levels are elevated in obesity. Maternal plasma leptin levels are increased during normal pregnancy, likely because of production in the placenta. In obese pregnant women, leptin levels are elevated in plasma, placenta, umbilical cord and fetus compared to non-obese pregnant women. Leptin is produced also by the fetus and is potentially involved in offspring brain development, likely through activation of pro-inflammatory cytokines with downstream effects on neurotransmitters influencing behaviors. Thus, leptin signaling stimulates pro-inflammatory cytokine secretion and influences cortisol release, serotonin and dopaminergic pathways, brain-derived neurotrophic factor (BDNF) signaling and hippocampal synaptic plasticity [93]. Altered leptin levels have been implicated in depression [94]. Elevated early childhood leptin levels in plasma, but not in cord blood, have been associated with an increased risk for autism [95], and associations between leptin levels and other behaviors have been reported from rodent models [93].

Oxytocin is produced primarily by the hypothalamus while its receptors are present both in the nervous system and peripherally, e.g., the adipose tissue. Elevated oxytocin levels influence food intake, adipose tissue metabolism and insulin sensitivity [96, 97]. Oxytocin deficient mice develop late-onset obesity despite normal food intake. Male offspring to pregnant dams on HFD had upregulated oxytocin receptor mRNA through epigenetic changes in the developing hippocampus [98]. Oxytocin modulates a wide range of neurotransmitter and neuromodulator activities and is well known to regulate social behavior, and might be linked to the pathogenesis of neuropsychiatric disorders, such as autism, schizophrenia and eating disorders [99, 100]. Additionally, oxytocin levels were reported to be critical for the developmental GABA switch from being excitatory to being an inhibitory neurotransmitter in rats [101], while lack of this switch induced autism-like behavior.

Epigenetic effects of maternal obesity and diabetes

The effects of hyperglycemia are in rodent models partly mediated by epigenetic changes, being modifications of histones, DNA and noncoding RNAs ultimately influencing

gene expression [102]. Indeed, maternal hyperglycemia is associated with increased DNA methylation in specific genes in offspring, inducing chronic effects for offspring development [103]. Furthermore, methylation-mediated epigenetic mechanisms for intergenerational susceptibility to metabolic disorders were found in a mouse model for GDM [104]. Epigenetic effects of obesity and diabetes on the offspring have in models been shown to occur not only at the fetus level, but also already in the oocyte and sperm [103–106] implying an influence of both maternal and paternal metabolic disorder [103–107]. Reported DNA methylation changes of maternal metabolic state with putative effects in the brain include, but are not limited to, those on offspring leptin signaling [93, 108].

In addition to metabolically induced epigenetic changes in the nuclear genome, the effects of maternal obesity and diabetes on mitochondria and mitochondrial dysfunction [109] might be considered a possible mediator of maternal-specific effects on the offspring, since mitochondrial DNA is inherited from the mother. Mitochondrial dysfunction has been suggested to be a mechanism underlying the pathogenesis of a range of neuropsychiatric disorders such as depression, schizophrenia and bipolar disorder [110].

Immune activity effects

Low-grade inflammation is commonly seen in obese and/or diabetic pregnant mothers. Pro-inflammatory cytokines passing the placenta to the fetus exposing the offspring brain during gestation are known to influence the development of neural pathways regulating behavior, such as the hypothalamic-pituitary-adrenal (HPA) axis, and serotonergic and dopaminergic systems and BDNF levels [60]. IL-6 is an early key pro-inflammatory cytokine. A recent longitudinal study found that maternal IL-6 concentrations during pregnancy were associated with neonate differences in functional brain networks for social, emotional and cognitive development, and subsequently in concert with working memory performance in 2-year-old offspring [111]. Higher levels of IL-6 may lead to offspring cognitive and behavioral deficits by altering the formation of synapses [112]. Pro-inflammatory cytokines, as well as BDNF, influence the differentiation and survival of neurons, synaptic plasticity and hence functional connectivity, essential for neurodevelopment and behavior, where also microglia play a key role [113, 114].

Microglia are motile myeloid cells in the brain, which play a critical role in neurodevelopment through regulating both neurogenesis and pruning, besides having traditional macrophage-type roles. Excess exposure to pro-inflammatory cytokines in the developing brain induces improper activation of microglia, resulting in improper

support and regulation of neuronal activity, impeding neuron differentiation and survival [113, 115, 116]. Rodent studies showed that dysregulation of microglia is associated with autism and schizophrenia [117], and microglia play an active part in obesity-related cognitive decline by phagocytosis of synapses [118].

Glucocorticoids and the hypothalamic-pituitary-adrenal (HPA) axis

Inflammation is known to upregulate the HPA axis [119]. The HPA axis regulates the neuroendocrine stress response through circulating cortisol, or in rodent corticosterone. A long-term overactive HPA axis increases the risk for impaired hippocampal glucocorticoid receptor (GR) feedback, elevated stress susceptibility and depressive and anxiety phenotypes. In mice and rats, maternal HFD has been reported to lead to increased maternal levels of corticosterone, which under this diet more readily passed through the placenta to the fetus [120]. The offspring had long-term elevated corticosterone levels, a dysregulated HPA-axis and were more sensitive to stressors with amygdala playing a role [121]. In humans, higher maternal early pregnancy BMI was reported to be associated with lower morning salivary cortisol in the offspring at adult age [122]. The placenta is a main source of corticotrophin releasing factor (CRF) [123], which feeds back to both the fetal and maternal pituitary to secrete ACTH stimulating cortisol/corticosterone production [124, 125]. Placental CRF plays a crucial role in regulating the fetal HPA axis [124, 126]. In rodent studies, the reduced HPA axis sensitivity and anxiety-like behaviors in offspring of dams with overactive HPA axis during pregnancy was in part explained by an attenuated hippocampal GR expression [127, 128]. Also immune activity and psychosocial stress causes elevated glucocorticoid levels [129]. Maternal psychosocial stress is known to long-term modify the offspring HPA axis activity epigenetically towards increased stress sensitivity [130] and suicide risk [131, 132].

Serotonergic and dopaminergic system effects

Changes in development of the serotonergic system and in serotonin signaling have been observed in rodent and non-human primate models owing to maternal inflammation or a HFD, leading to increased risk for behavioral abnormalities in offspring [133–135]. Altered dopamine sensitivity, as well as abnormal dopamine and *BDNF* expression are also documented in rats of mothers fed with HFD [60, 136, 137]. Moreover, maternal inflammation, modeled with IL-6 and

leptin, has been associated with dopamine signaling in offspring [138]. Serotonin and dopamine are known key neurotransmitters in psychopathology, and have together with BDNF been suggested by a growing body of evidence to also be linked to the pathogenesis of several neuropsychiatric disorders [99, 139].

The gut-brain axis

Another putative link from maternal obesity and diabetes to offspring neuropsychiatric disorders is a putative maternal gut-fetal brain axis. HFD dramatically alters the intestinal microbiota, and the gut bacterial microbiota is less diverse and more inflammatory in persons with obesity or diabetes [140]. A less diverse gut microbiota has been reported also in psychiatric patients, and feces from patients with ASD, depression or schizophrenia transferred to the rodent intestine produced disorder-related behaviors and biochemical modulations [141–143]. The gut microbiota communicates with the enteric nervous system in the gastrointestinal organs, which signals via vagus and ganglia to the central nervous system. In fact, gut bacteria show species-specific production of neuroactive substances, e.g., dopamine, serotonin and GABA neurotransmitters. Other key routes of the gut-brain axis include the bacterial fermentation metabolites short chain fatty acids (SCFAs), and immune activation, both regulating the function of the intestinal and blood-brain barriers [144]. The SCFAs pass the blood-brain barrier and have broad effects on nervous system physiology such as mitochondrial function and microglial maturation and activation [145, 146]. SCFAs at physiological levels regulate early growth and proliferation of human neural proliferating cells [147]. Thus, gut microbiota metabolites, such as SCFAs, might have an effect on the offspring neurodevelopment and hence mediate a putative maternal-gut fetal-brain axis. Also, a maternal gut bacterial flora activating Th17-cell has been reported to increase the risk of rodent offspring behavior and brain structure abnormalities resembling ASD after exposure to maternal immune activation, such as infection [148]. Both disruptions in neuronal architecture by direct intracerebral action through interleukin-17a pathway, and altered signatures of gut microbiota have been documented in offspring with maternal immune activation [72].

Genetic factors

As a result of the altered intrauterine environment, as aforementioned, neurogenesis/apoptosis, synaptic pruning, neuronal migration, and neuronal connection could be affected [149, 150]. The symptom and functionality

outcomes might also in part depend on factors such as genetic and postnatal factors. Obesity and type 2 diabetes are known to be heritable, the inherited susceptibility of which relate to accumulation of many common DNA variants [151]. Recent genome-wide-association-studies (GWAS) revealed that more than 200 loci associated with type 2 diabetes and obesity traits [152–154]. Neurodevelopmental and psychiatric disorders are also moderately (depressive, anxiety, eating and sleeping disorders) to highly (ASD, AHDH, bipolar and psychotic disorders) heritable [155]. Notably, children with ADHD or ASD have been reported to have an enhanced risk for developing obesity [156, 157]. One possibility is that obesity and neurodevelopmental disorders share some common genetic or metabolic pathways. GWAS loci associated with obesity have been shown to be nearby genes involved in appetite, energy homeostasis and mood regulation [158–160]. Additionally, the gene for β 2-Adrenoceptor (ADRB2, a G protein-coupled receptor) was involved in the circulatory, muscle, and digestive system. This gene was also linked to insulin resistance [161], obesity/diabetes [162, 163], and psychiatric disorders such as autism [164].

Finally, maternal pre-pregnancy obesity and diabetes seem to jointly potentiate their offspring to adverse neurodevelopment [12, 165, 166]. The timing of obesity and/or diabetes onset might be important in determining the offspring neurodevelopmental outcomes. The most vulnerable period would be peri-conceptional and early pregnancy, during which period the epigenetic programming, placentation and fetal brain organogenesis happens [167]. Environmental exposures during postnatal life such as familial parenting style may also influence the offspring neurodevelopment [168].

Challenges for future research

The extensive adjustment for potential confounders in previous studies might induce underestimation of effect sizes. On the other hand, sibling pair analyses suggest the influence of elusive familial factors on the association between maternal obesity and offspring ASD and ADHD. Thus, the causality of the observed associations remains unclear. Further, ASD and ADHD often co-occur. Future studies should tease out common and unique factors contributing to these disorders. Still, experimental research in rodents clearly supports a causal effect of a dysmetabolic milieu, for germ cells and fetus, resulting in phenotypic effects resembling some characteristics of pediatric neurodevelopmental and psychiatric disorders. Hence, alongside further experimental mechanistic research, large sophisticated prospective studies controlling for familial confounding are needed to obtain further insights into the multiple effectors

and underlying mechanisms of the observed associations, such as sibling-comparison and maternal-paternal comparison studies and Mendelian randomization studies. Future studies should carefully consider gene \times environmental interactions, which are likely underlying most of the neurodevelopmental disorders, hence exposure and diagnoses outcome data should be combined with multi-omics profiling (genome, epigenome, metabolome). Especially, sibling pair analyses (including twin pairs) combined with multi-omics profiling (genome, epigenome, metabolome) would be powerful in delineating specific familial factors. Here, detailed information and assessments are important, such as repeated measurements of maternal BMI, body composition and metabolic status from first trimester and onwards, as well as specific maternal lifestyle and nutritional factors that might strengthen effects of maternal obesity and diabetes on offspring neuropsychiatric disorders. Finally, although specific dietary interventions exist, such as omega-3 supplementation, there is a lack of innovative and effective intervention research starting in the first trimester with long-term follow-up of offspring regarding the moderation of maternal metabolic exposures, before or during pregnancy, on the risk of offspring neurodevelopmental or psychiatric disorders [169].

Concluding remarks

This narrative review highlights previous research regarding associations of maternal obesity and diabetes with neurodevelopmental and psychiatric disorders in offspring. The associations between maternal obesity on the one hand, and offspring ASD, ADHD and cognitive function on the other hand, have been extensively studied in large cohorts with results displaying modest effect sizes after adjustment for confounding maternal and birth factors. Those effects are reported to likely be explained in part by an obesity-associated intrauterine milieu, and in part by maternal genetic background and other familial factors. The importance of the latter factors was concluded through analyses applying a sibling analysis design or a paternal-maternal-comparison. The influence of maternal obesity on other psychiatric disorders is less well studied, but there are reports of associations with increased risk for offspring depression, anxiety, schizophrenia and eating disorders, at modest effect sizes. The effect of maternal T2DM and GDM on offspring ASD, and that of maternal T1DM and GDM on offspring ADHD have been explored, again revealing modest positive effect sizes. Here, there are no reports of sibling analyses or maternal-paternal comparisons. Notably, a few studies have reported larger effect sizes on risks for ASD and ADHD for mothers with both obesity and diabetes, which might reflect a more

metabolically impaired intrauterine milieu. This review also provides an overview of plausible underlying mechanisms, which support both an actual involvement of a metabolically dysregulated intrauterine milieu on neurodevelopment, and familial factors, although interpretation of rodent model findings into the human case must be done with caution. The current knowledge on effectors in the intrauterine milieu, which is based primarily on rodent models, proposes a role of particularly hyperglycemia-induced epigenetic effects and pro-inflammatory cytokines. Prospective maternal-paternal comparison and sibling-comparison studies, experimental animal model studies and randomized controlled trials are required to examine the causality, underlying mechanisms and the potential for prevention of maternal metabolic exposures.

Funding This study was supported by the THL National Institute for Health and Welfare: Drug and pregnancy project (MG), the Swedish Research Council (CL), the regional agreement on medical training and clinical research (ALF) between Stockholm County Council and Karolinska Institutet Stockholm County Council (CL), the China Scholarship Council (www.csc.edu.cn, LK and XC) and the Swedish Brain Foundation (CL), the Joint Research Funds for Shandong University and Karolinska Institute (CL and XC).

Author contributions CL conceptualized the study, designed the study and led the manuscript writing; LK conducted literature search and wrote the initial draft; XC contributed to manuscript writing; all the authors critically reviewed the manuscript and approved the final manuscript.

Compliance with ethical standards

Conflict of interest The authors declare that they have no conflict of interest.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

References

1. Chen C, Xu X, Yan Y. Estimated global overweight and obesity burden in pregnant women based on panel data model. *PLoS One*. 2018;13:e0202183.

2. Ogden CL, Carroll MD, Fryar CD, Flegal KM. Prevalence of obesity among adults and youth: United States, 2011–2014. *NCHS Data Brief*. 2015;2019:1–8.
3. Guariguata L, Linnenkamp U, Beagley J, Whiting DR, Cho NH. Global estimates of the prevalence of hyperglycaemia in pregnancy. *Diabetes Res Clin Pract*. 2014;103:176–85.
4. Magon N, Chauhan M. Pregnancy in type 1 diabetes mellitus: how special are special issues? *N Am J Med Sci*. 2012;4:250.
5. Lawrence JM, Contreras R, Chen W, Sacks DA. Trends in the prevalence of pre-existing diabetes and gestational diabetes mellitus among a racially/ethnically diverse population of pregnant women, 1999–2005. *Diabetes Care*. 2008;31:899–904.
6. Gaillard R, Felix JF, Duijts L, Jaddoe VW. Childhood consequences of maternal obesity and excessive weight gain during pregnancy. *Acta Obstetrica et Gynecol Scandinavica*. 2014;93:1085–9.
7. Gaillard R. Maternal obesity during pregnancy and cardiovascular development and disease in the offspring. *Eur J Epidemiol*. 2015;30:1141–52.
8. Poston L, Caleyachetty R, Cnattingius S, Corvalán C, Uauy R, Herring S, et al. Preconceptional and maternal obesity: epidemiology and health consequences. *Lancet Diabetes Endocrinol*. 2016;4:1025–36.
9. Kong L, Nilsson IA, Gissler M, Lavebratt C. Associations of maternal diabetes and body mass index with offspring birth weight and prematurity. *JAMA Pediatrics*. 2019;173:371–8.
10. Edlow AG. Maternal obesity and neurodevelopmental and psychiatric disorders in offspring. *Prenatal Diagn*. 2017;37:95–110.
11. Nomura Y, Marks DJ, Grossman B, Yoon M, Loudon H, Stone J, et al. Exposure to gestational diabetes mellitus and low socioeconomic status: effects on neurocognitive development and risk of attention-deficit/hyperactivity disorder in offspring. *Arch Pediatrics Adolesc Med*. 2012;166:337–43.
12. Kong L, Norstedt G, Schalling M, Gissler M, Lavebratt C. The risk of offspring psychiatric disorders in the setting of maternal obesity and diabetes. *Pediatrics*. 2018;142:e20180776.
13. Xiang AH, Wang X, Martinez MP, Getahun D, Page KA, Buchanan TA, et al. Maternal gestational diabetes mellitus, type 1 diabetes, and type 2 diabetes during pregnancy and risk of ADHD in offspring. *Diabetes Care*. 2018;41:2502–8.
14. Xiang AH, Wang X, Martinez MP, Walthall JC, Curry ES, Page K, et al. Association of maternal diabetes with autism in offspring. *JAMA*. 2015;313:1425–34.
15. Li M, Fallin MD, Riley A, Landa R, Walker SO, Silverstein M, et al. The association of maternal obesity and diabetes with autism and other developmental disabilities. *Pediatrics*. 2016;137:e20152206.
16. Wan H, Zhang C, Li H, Luan S, Liu C. Association of maternal diabetes with autism spectrum disorders in offspring: a systemic review and meta-analysis. *Medicine*. 2018;97:e9438.
17. Catalano P. The impact of gestational diabetes and maternal obesity on the mother and her offspring. *J Dev Origins Health Dis*. 2010;1:208–15.
18. Nousen EK, Franco JG, Sullivan EL. Unraveling the mechanisms responsible for the comorbidity between metabolic syndrome and mental health disorders. *Neuroendocrinology*. 2013;98:254–66.
19. Grant R, Nozyce M. Proposed changes to the American Psychiatric Association diagnostic criteria for autism spectrum disorder: Implications for young children and their families. *Maternal Child Health J*. 2013;17:586–92.
20. Rivera HM, Christiansen KJ, Sullivan EL. The role of maternal obesity in the risk of neuropsychiatric disorders. *Front Neurosci*. 2015;9:194.
21. Van Lieshout R, Taylor V, Boyle M. Pre-pregnancy and pregnancy obesity and neurodevelopmental outcomes in offspring: a systematic review. *Obesity Rev*. 2011;12:e548–e559.
22. Contu L, Hawkes C. A review of the impact of maternal obesity on the cognitive function and mental health of the offspring. *Int J Mol Sci*. 2017;18:1093.
23. Lei X-Y, Li Y-J, Ou J-J, Li Y-M. Association between parental body mass index and autism spectrum disorder: a systematic review and meta-analysis. *Eur Child Adolesc Psy*. 2019;28:933–47.
24. Wang Y, Tang S, Xu S, Weng S, Liu Z. Maternal body mass index and risk of autism spectrum disorders in offspring: a meta-analysis. *Sci Rep*. 2016;6:34248.
25. Sanchez CE, Barry C, Sabhlok A, Russell K, Majors A, Kollins SH, et al. Maternal pre-pregnancy obesity and child neurodevelopmental outcomes: a meta-analysis. *Obesity Rev*. 2018;19:464–84.
26. Li Y-M, Ou J-J, Liu L, Zhang D, Zhao J-P, Tang S-Y. Association between maternal obesity and autism spectrum disorder in offspring: a meta-analysis. *J Autism Dev Disorders*. 2016;46:95–102.
27. Krakowiak P, Walker CK, Bremer AA, Baker AS, Ozonoff S, Hansen RL, et al. Maternal metabolic conditions and risk for autism and other neurodevelopmental disorders. *Pediatrics*. 2012;129:e1121–e1128.
28. Gardner RM, Lee BK, Magnusson C, Rai D, Frisell T, Karlsson H, et al. Maternal body mass index during early pregnancy, gestational weight gain, and risk of autism spectrum disorders: results from a Swedish total population and discordant sibling study. *Int J Epidemiol*. 2015;44:870–83.
29. Surén P, Gunnes N, Roth C, Bresnahan M, Hornig M, Hirtz D, et al. Parental obesity and risk of autism spectrum disorder. *Pediatrics*. 2014;133:e1128–e1138.
30. Casas M, Fornis J, Martínez D, Guxens M, Fernandez-Somoano A, Ibarluzea J, et al. Maternal pre-pregnancy obesity and neuropsychological development in pre-school children: a prospective cohort study. *Pediatric Res*. 2017;82:596.
31. Xu G, Jing J, Bowers K, Liu B, Bao W. Maternal diabetes and the risk of autism spectrum disorders in the offspring: a systematic review and meta-analysis. *J Autism Dev Disorders*. 2014;44:766–75.
32. Lyall K, Pauls DL, Spiegelman D, Ascherio A, Santangelo SL. Pregnancy complications and obstetric suboptimality in association with autism spectrum disorders in children of the Nurses' Health Study II. *Autism Res*. 2012;5:21–30.
33. Dodds L, Fell DB, Shea S, Armson BA, Allen AC, Bryson S. The role of prenatal, obstetric and neonatal factors in the development of autism. *J Autism Dev Disorders*. 2011;41:891–902.
34. Rodriguez A, Miettunen J, Henriksen TB, Olsen J, Obel C, Taanila A, et al. Maternal adiposity prior to pregnancy is associated with ADHD symptoms in offspring: evidence from three prospective pregnancy cohorts. *Int J Obesity*. 2008;32:550.
35. Bergmann S, Schlesier-Michel A, Wendt V, Grube M, Keitel-Korndörfer A, Gausche R, et al. Maternal weight predicts children's psychosocial development via parenting stress and emotional availability. *Front Psychol*. 2016;7:1156.
36. Chen Q, Sjölander A, Långström N, Rodriguez A, Serlachius E, D'Onofrio BM, et al. Maternal pre-pregnancy body mass index and offspring attention deficit hyperactivity disorder: a population-based cohort study using a sibling-comparison design. *Int J Epidemiol*. 2013;43:83–90.
37. Musser ED, Willoughby MT, Wright S, Sullivan EL, Stadler DD, Olson BF, et al. Maternal prepregnancy body mass index and offspring attention-deficit/hyperactivity disorder: a quasi-experimental sibling-comparison, population-based design. *J Child Psychol Psychiatry*. 2017;58:240–7.
38. Instanes JT, Halmøy A, Engeland A, Haavik J, Furu K, Klungsoyr K. Attention-deficit/hyperactivity disorder in

- offspring of mothers with inflammatory and immune system diseases. *Biol Psychiatry*. 2017;81:452–9.
39. Nielsen PR, Benros ME, Dalsgaard S. Associations between autoimmune diseases and attention-deficit/hyperactivity disorder: a nationwide study. *J. Am Acad Child Adolesc Psychiatry*. 2017;56:234–40. e1.
 40. Ji J, Chen T, Sundquist J, Sundquist K. Type 1 diabetes in parents and risk of attention deficit/hyperactivity disorder in offspring: a population-based study in Sweden. *Diabetes Care*. 2018;41:770–4.
 41. Veena SR, Gale CR, Krishnaveni GV, Kehoe SH, Srinivasan K, Fall CH. Association between maternal nutritional status in pregnancy and offspring cognitive function during childhood and adolescence; a systematic review. *BMC Pregnancy Childbirth*. 2016;16:220.
 42. Basatemur E, Gardiner J, Williams C, Melhuish E, Barnes J, Sutcliffe A. Maternal prepregnancy BMI and child cognition: a longitudinal cohort study. *Pediatrics*. 2013;131:56–63.
 43. Bliddal M, Olsen J, Størvring H, Eriksen H-LF, Kesmodel US, Sørensen TI, et al. Maternal pre-pregnancy BMI and intelligence quotient (IQ) in 5-year-old children: a cohort based study. *PLoS One*. 2014;9:e94498.
 44. Casas M, Chatzi L, Carsin A-E, Amiano P, Guxens M, Kogevinas M, et al. Maternal pre-pregnancy overweight and obesity, and child neuropsychological development: two Southern European birth cohort studies. *Int J Epidemiol*. 2013;42:506–17.
 45. Hinkle S, Schieve L, Stein A, Swan D, Ramakrishnan U, Sharma A. Associations between maternal prepregnancy body mass index and child neurodevelopment at 2 years of age. *Int J Obesity*. 2012;36:1312.
 46. Pugh SJ, Richardson GA, Hutcheon JA, Himes KP, Brooks MM, Day NL, et al. Maternal obesity and excessive gestational weight gain are associated with components of child cognition. *J Nutr*. 2015;145:2562–9.
 47. Tanda R, Salsberry PJ, Reagan PB, Fang MZ. The impact of prepregnancy obesity on children's cognitive test scores. *Maternal Child Health J*. 2013;17:222–9.
 48. Brion M-J, Zeegers M, Jaddoe V, Verhulst F, Tiemeier H, Lawlor DA, et al. Intrauterine effects of maternal prepregnancy overweight on child cognition and behavior in 2 cohorts. *Pediatrics*. 2011;127:e202–e211.
 49. Craig WY, Palomaki GE, Neveux LM, Haddow JE. Maternal body mass index during pregnancy and offspring neurocognitive development. *Obstetric Med*. 2013;6:20–25.
 50. Huang L, Yu X, Keim S, Li L, Zhang L, Zhang J. Maternal prepregnancy obesity and child neurodevelopment in the collaborative perinatal project. *Int. J. Epidemiol*. 2014;43:783–92.
 51. Fraser A, Nelson SM, Macdonald-Wallis C, Lawlor DA. Associations of existing diabetes, gestational diabetes, and glycosuria with offspring IQ and educational attainment: the Avon Longitudinal Study of Parents and Children. *Exper. Diabetes Res*. 2012;2012:963735.
 52. Veena S, Krishnaveni G, Srinivasan K, Kurpad A, Muthayya S, Hill J, et al. Childhood cognitive ability: relationship to gestational diabetes mellitus in India. *Diabetologia*. 2010;53:2134–8.
 53. Fraser A, Almqvist C, Larsson H, Långström N, Lawlor DA. Maternal diabetes in pregnancy and offspring cognitive ability: sibling study with 723,775 men from 579,857 families. *Diabetologia*. 2014;57:102–9.
 54. Clausen TD, Mortensen EL, Schmidt L, Mathiesen ER, Hansen T, Jensen DM, et al. Cognitive function in adult offspring of women with Type 1 diabetes. *Diabetic Med*. 2011;28:838–44.
 55. Robles MC, Campoy C, Fernandez LG, Lopez-Pedrosa JM, Rueda R, Martin MJ. Maternal diabetes and cognitive performance in the offspring: a systematic review and meta-analysis. *PLoS One*. 2015;10:e0142583.
 56. Robinson M, Zubrick SR, Pennell CE, Van Lieshout RJ, Jacoby P, Beilin LJ, et al. Pre-pregnancy maternal overweight and obesity increase the risk for affective disorders in offspring. *J. Dev. Origins Health Dis*. 2013;4:42–48.
 57. Khandaker G, Dikken C, Jones P. Does maternal body mass index during pregnancy influence risk of schizophrenia in the adult offspring? *Obesity Rev*. 2012;13:518–27.
 58. Mackay E, Dalman C, Karlsson H, Gardner RM. Association of gestational weight gain and maternal body mass index in early pregnancy with risk for nonaffective psychosis in offspring. *JAMA Psychiatry*. 2017;74:339–49.
 59. Allen KL, Byrne SM, Oddy WH, Crosby RD. DSM-IV-TR and DSM-5 eating disorders in adolescents: prevalence, stability, and psychosocial correlates in a population-based sample of male and female adolescents. *J. Abnormal Psychol*. 2013;122:720.
 60. Piazza FV, Segabinazi E, de Meireles ALF, Mega F, de Figueiredo Spindler C, Augustin OA, et al. Severe uncontrolled maternal hyperglycemia induces microsomnia and neurodevelopment delay accompanied by apoptosis, cellular survival, and neuroinflammatory deregulation in rat offspring hippocampus. *Cell. Mol. Neurobiol*. 2019;39:401–14.
 61. Menting MD, van de Beek C, Mintjens S, Wever KE, Korosi A, Ozanne SE, et al. The link between maternal obesity and offspring neurobehavior: a systematic review of animal experiments. *Neurosci. Biobehav. Rev*. 2019;98:107–21.
 62. Satrom KM, Ennis K, Sweis BM, Matveeva TM, Chen J, Hanson L, et al. Neonatal hyperglycemia induces CXCL10/CXCR3 signaling and microglial activation and impairs long-term synaptogenesis in the hippocampus and alters behavior in rats. *J Neuroinflammation*. 2018;15:82.
 63. Jing Y-H, Song Y-F, Yao Y-M, Yin J, Wang D-g, Gao L-P. Retardation of fetal dendritic development induced by gestational hyperglycemia is associated with brain insulin/IGF-I signals. *Int. J. Dev. Neurosci*. 2014;37:15–20.
 64. Sullivan EL, Nousen EK, Chamblou KA. Maternal high fat diet consumption during the perinatal period programs offspring behavior. *Physiol Behav*. 2014;123:236–42.
 65. Catalano PM, Presley L, Minium J, Hauguel-de Mouzon S. Fetuses of obese mothers develop insulin resistance in utero. *Diabetes Care*. 2009;32:1076–80.
 66. Kahn SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. *Nature*. 2006;444:840.
 67. Pantham P, Aye ILH, Powell TL. Inflammation in maternal obesity and gestational diabetes mellitus. *Placenta*. 2015;36:709–15.
 68. Hauguel-de Mouzon S, Lepercq J, Catalano P. The known and unknown of leptin in pregnancy. *Am J Obstetrics Gynecol*. 2006;194:1537–45.
 69. Westgate JA, Lindsay RS, Beattie J, Pattison NS, Gamble G, Mildenhall LF, et al. Hyperinsulinemia in cord blood in mothers with type 2 diabetes and gestational diabetes mellitus in New Zealand. *Diabetes Care*. 2006;29:1345–50.
 70. Lackey DE, Olefsky JM. Regulation of metabolism by the innate immune system. *Nat Rev Endocrinol*. 2016;12:15.
 71. Sureshchandra S, Marshall NE, Wilson RM, Barr T, Rais M, Purnell JQ, et al. Inflammatory determinants of pregravid obesity in placenta and peripheral blood. *Front Physiol*. 2018;9:1089.
 72. Jiang NM, Cowan M, Moonah SN, Petri WA Jr. The impact of systemic inflammation on neurodevelopment. *Trends Mol Med*. 2018;24:794–804.
 73. O'Kusky J, Ye P. Neurodevelopmental effects of insulin-like growth factor signaling. *Front Neuroendocrinol*. 2012;33:230–51.
 74. Baud O, Berkane N. Hormonal changes associated with intrauterine growth restriction: impact on the developing brain and future neurodevelopment. *Front Endocrinol*. 2019;10:179.

75. Ratnayake U, Quinn T, Walker D, Dickinson H. Cytokines and the neurodevelopmental basis of mental illness. *Front Neurosci.* 2013;7:180.
76. Wang X, Yang T, Miao J, Liu H, Wu K, Guo J, et al. Correlation between maternal and fetal insulin resistance in pregnant women with gestational diabetes mellitus. *Clin Lab.* 2018;64:945–53.
77. Ornoy A, Reece EA, Pavlinkova G, Kappen C, Miller RK. Effect of maternal diabetes on the embryo, fetus, and children: congenital anomalies, genetic and epigenetic changes and developmental outcomes. *Birth Defects Res Part C Embryo Today Rev.* 2015;105:53–72.
78. Heerwagen MJ, Miller MR, Barbour LA, Friedman JE. Maternal obesity and fetal metabolic programming: a fertile epigenetic soil. *Am J Physiol Regul Integr Comp Physiol.* 2010;299:R711–R722.
79. Carpita B, Muti D, Dell’Osso L. Oxidative stress, maternal diabetes, and autism spectrum disorders. *Oxid Med Cell Longev.* 2018;9:3717215.
80. Jarvie E, Hauguel-de-Mouzon S, Nelson SM, Sattar N, Catalano PM, Freeman DJ. Lipotoxicity in obese pregnancy and its potential role in adverse pregnancy outcome and obesity in the offspring. *Clinical Science.* 2010;119:123–9.
81. Park S, Jang A, Bouret SG. Maternal obesity-induced endoplasmic reticulum stress causes metabolic alterations and abnormal hypothalamic development in the offspring. *PLoS Biol.* 2020;18:e3000296.
82. Denison FC, Roberts KA, Barr SM, Norman JE. Obesity, pregnancy, inflammation, and vascular function. *Reproduction.* 2010;140:373–85.
83. Bilbo SD, Tsang V. Enduring consequences of maternal obesity for brain inflammation and behavior of offspring. *FASEB J.* 2010;24:2104–15.
84. Huleihel M, Golan H, Hallak M. Intrauterine infection/inflammation during pregnancy and offspring brain damages: possible mechanisms involved. *Reprod Biol Endocrinol.* 2004;2:17.
85. Wellen KE, Hotamisligil GS. Inflammation, stress, and diabetes. *J Clin Investig.* 2005;115:1111–9.
86. Zatterale F, Longo M, Naderi J, Raciti GA, Desiderio A, Miele C, et al. Chronic adipose tissue inflammation linking obesity to insulin resistance and type 2 diabetes. *Front Physiol.* 2020;10:1607.
87. Richardson AC, Carpenter MW. Inflammatory mediators in gestational diabetes mellitus. *Obstetrics Gynecol Clin North Am.* 2007;34:213–24.
88. Simerly RB. Hypothalamic substrates of metabolic imprinting. *Physiol Behav.* 2008;94:79–89.
89. Halaas JL, Gajiwala KS, Maffei M, Cohen SL, Chait BT, Rabinowitz D, et al. Weight-reducing effects of the plasma protein encoded by the obese gene. *Science.* 1995;269:543–6.
90. Sun KL, Watson K, Angal S, Bakkila BF, Gorelik AJ, Leslie SM, et al. Neural and endocrine correlates of early life abuse in youth with depression and obesity. *Front Psychiatry.* 2018;9:721.
91. Leonard BE, Wegener G. Inflammation, insulin resistance and neuroprogression in depression. *Acta Neuropsychiatrica.* 2020;32:1–9.
92. Silva L, de Menezes N, Lam M, Soares CN, Munoz D, Milev R, et al. Insulin resistance as a shared pathogenic mechanism between Depression and Type 2 diabetes. *Front Psychiatry.* 2019;10:57.
93. Valteau JC, Sullivan EL. The impact of leptin on perinatal development and psychopathology. *J Chem Neuroanatomy.* 2014;61:221–32.
94. Ge T, Fan J, Yang W, Cui R, Li B. Leptin in depression: a potential therapeutic target. *Cell Death Disease.* 2018;9:1–10.
95. Raghavan R, Zuckerman B, Hong X, Wang G, Ji Y, Paige D, et al. Fetal and infancy growth pattern, cord and early childhood plasma leptin, and development of autism spectrum disorder in the Boston birth cohort. *Autism Res.* 2018;11:1416–31.
96. Deblon N, Veyrat-Durebex C, Bourgoin L, Caillon A, Bussier A-L, Petrosino S, et al. Mechanisms of the anti-obesity effects of oxytocin in diet-induced obese rats. *PLoS one.* 2011;6:e25565.
97. Lawson EA. The effects of oxytocin on eating behaviour and metabolism in humans. *Nat Rev Endocrinol.* 2017;13:700.
98. Glendining KA, Jasoni CL. Maternal high fat diet-induced obesity modifies histone binding and expression of oxttr in offspring hippocampus in a sex-specific manner. *Int J Mol Sci.* 2019;20:329.
99. Romano A, Tempesta B, Micioni Di Bonaventura MV, Gaetani S. From autism to eating disorders and more: the role of oxytocin in neuropsychiatric disorders. *Front Neurosci.* 2016;9:497.
100. Huber D, Veinante P, Stoop R. Vasopressin and oxytocin excite distinct neuronal populations in the central amygdala. *Science.* 2005;308:245–8.
101. Tyzio R, Nardou R, Ferrari DC, Tsintsadze T, Shahrokhi A, Eftekhari S, et al. Oxytocin-mediated GABA inhibition during delivery attenuates autism pathogenesis in rodent offspring. *Science.* 2014;343:675–9.
102. Zhang Y, Zhang X, Shi J, Tuorto F, Li X, Liu Y, et al. Dnm2 mediates intergenerational transmission of paternally acquired metabolic disorders through sperm small non-coding RNAs. *Nat Cell biology.* 2018;20:535–40.
103. Yu D-Q, Lv P-P, Yan Y-S, Xu G-X, Sadhukhan A, Dong S, et al. Intrauterine exposure to hyperglycemia retards the development of brown adipose tissue. *FASEB J.* 2019;33:5425–39.
104. Zhu H, Chen B, Cheng Y, Zhou Y, Yan Y-S, Luo Q, et al. Insulin therapy for gestational diabetes mellitus does not fully protect offspring from diet-induced metabolic disorders. *Diabetes.* 2019;68:696–708.
105. Ou X-H, Zhu C-C, Sun S-C. Effects of obesity and diabetes on the epigenetic modification of mammalian gametes. *J Cell Physiol.* 2019;234:7847–55.
106. Sales VM, Ferguson-Smith AC, Patti M-E. Epigenetic mechanisms of transmission of metabolic disease across generations. *Cell Metabol.* 2017;25:559–71.
107. Thion MS, Low D, Silvin A, Chen J, Grisel P, Schulte-Schrepping J, et al. Microbiome influences prenatal and adult microglia in a sex-specific manner. *Cell.* 2018;172:500–16. e16.
108. Glendining K, Higgins M, Fisher L, Jasoni C. Maternal obesity modulates sexually dimorphic epigenetic regulation and expression of leptin receptor in offspring hippocampus. *Brain Behav Immun.* 2020;S0889–1591:31512–0.
109. Saben JL, Boudoures AL, Asghar Z, Thompson A, Drury A, Zhang W, et al. Maternal metabolic syndrome programs mitochondrial dysfunction via germline changes across three generations. *Cell Rep.* 2016;16:1–8.
110. Rezin GT, Amboni G, Zugno AI, Quevedo J, Streck EL. Mitochondrial dysfunction and psychiatric disorders. *Neurochem Res.* 2008;34:1021.
111. Rudolph MD, Graham AM, Feczko E, Miranda-Dominguez O, Rasmussen JM, Nardos R, et al. Maternal IL-6 during pregnancy can be estimated from newborn brain connectivity and predicts future working memory in offspring. *Nat Neurosci.* 2018;21:765–72.
112. Estes ML, McAllister AK. Maternal immune activation: Implications for neuropsychiatric disorders. *Science.* 2016;353:772–7.
113. Vallieres L, Campbell IL, Gage FH, Sawchenko PE. Reduced hippocampal neurogenesis in adult transgenic mice with chronic astrocytic production of interleukin-6. *J Neurosci.* 2002;22:486–92.
114. Calabrese F, Rossetti AC, Racagni G, Gass P, Riva MA, Molteni R. Brain-derived neurotrophic factor: a bridge between inflammation and neuroplasticity. *Front Cellular Neurosci.* 2014;8:430.

115. Monje ML, Toda H, Palmer TD. Inflammatory blockade restores adult hippocampal neurogenesis. *Science*. 2003;302:1760–5.
116. Ye L, Huang Y, Zhao L, Li Y, Sun L, Zhou Y, et al. IL-1 β and TNF- α induce neurotoxicity through glutamate production: a potential role for neuronal glutaminase. *J Neurochem*. 2013;125:897–908.
117. Hong S, Stevens B. Microglia: phagocytosing to clear, sculpt, and eliminate. *Dev Cell*. 2016;38:126–8.
118. Cope EC, LaMarca EA, Monari PK, Olson LB, Martinez S, Zych AD, et al. Microglia play an active role in obesity-associated cognitive decline. *J Neurosci*. 2018;38:8889–904.
119. Chrousos GP. The hypothalamic–pituitary–adrenal axis and immune-mediated inflammation. *N Engl J Med*. 1995;332:1351–63.
120. Bellisario V, Panetta P, Balsevich G, Baumann V, Noble J, Raggi C, et al. Maternal high-fat diet acts as a stressor increasing maternal glucocorticoids' signaling to the fetus and disrupting maternal behavior and brain activation in C57BL/6J mice. *Psychoneuroendocrinology*. 2015;60:138–50.
121. Niu X, Wu X, Ying A, Shao B, Li X, Zhang W, et al. Maternal high fat diet programs hypothalamic-pituitary-adrenal function in adult rat offspring. *Psychoneuroendocrinology*. 2019;102:128–38.
122. Kumpulainen SM, Heinonen K, Kaseva N, Andersson S, Lano A, Reynolds RM, et al. Maternal early pregnancy body mass index and diurnal salivary cortisol in young adult offspring. *Psychoneuroendocrinology*. 2019;104:89–99.
123. Shibasaki T, Odagiri E, Shizume K, Ling N. Corticotropin-releasing factor-like activity in human placental extracts. *J Clin Endocrinol Metabol*. 1982;55:384–6.
124. Smith R, Mesiano S, Chan E-C, Brown S, Jaffe RB. Corticotropin-releasing hormone directly and preferentially stimulates dehydroepiandrosterone sulfate secretion by human fetal adrenal cortical cells. *J Clin Endocrinol Metabol*. 1998;83:2916–20.
125. Wadhwa PD, Sandman CA, CHICZ-DeMET A, Porto M. Placental CRH modulates maternal pituitary-adrenal function in human pregnancy. *Ann NY Acad Sci*. 1997;814:276–81.
126. Ng P. The fetal and neonatal hypothalamic–pituitary–adrenal axis. *Arch Disease Childhood Fetal Neonatal Ed*. 2000;82:F250–F254.
127. Welberg L, Seckl J, Holmes M. Prenatal glucocorticoid programming of brain corticosteroid receptors and corticotrophin-releasing hormone: possible implications for behaviour. *Neuroscience*. 2001;104:71–79.
128. Levitt NS, Lindsay RS, Holmes MC, Seckl JR. Dexamethasone in the last week of pregnancy attenuates hippocampal glucocorticoid receptor gene expression and elevates blood pressure in the adult offspring in the rat. *Neuroendocrinology*. 1996;64:412–8.
129. Webster JI, Sternberg EM. Role of the hypothalamic-pituitary-adrenal axis, glucocorticoids and glucocorticoid receptors in toxic sequelae of exposure to bacterial and viral products. *J Endocrinol*. 2004;181:207–21.
130. Efstathopoulos P, Andersson F, Melas PA, Yang LL, Villaescusa JC, R ugg J, et al. NR3C1 hypermethylation in depressed and bullied adolescents. *Transl Psychiatry*. 2018;8:1–8.
131. McGowan PO, Sasaki A, D'aleccio AC, Dymov S, Labont  B, Szyf M, et al. Epigenetic regulation of the glucocorticoid receptor in human brain associates with childhood abuse. *Nat Neurosci*. 2009;12:342.
132. Oberlander TF, Weinberg J, Papsdorf M, Grunau R, Misri S, Devlin AM. Prenatal exposure to maternal depression, neonatal methylation of human glucocorticoid receptor gene (NR3C1) and infant cortisol stress responses. *Epigenetics*. 2008;3:97–106.
133. Sullivan EL, Grayson B, Takahashi D, Robertson N, Maier A, Bethea CL, et al. Chronic consumption of a high-fat diet during pregnancy causes perturbations in the serotonergic system and increased anxiety-like behavior in nonhuman primate offspring. *J Neurosci*. 2010;30:3826–30.
134. Peleg-Raibstein D, Luca E, Wolfrum C. Maternal high-fat diet in mice programs emotional behavior in adulthood. *Behav Brain Res*. 2012;233:398–404.
135. Thompson JR, Valleau JC, Barling AN, Franco JG, DeCapo M, Bagley JL, et al. Exposure to a high-fat diet during early development programs behavior and impairs the central serotonergic system in juvenile non-human primates. *Front Endocrinol*. 2017;8:164.
136. Naef L, Srivastava L, Gratton A, Hendrickson H, Owens SM, Walker C-D. Maternal high fat diet during the perinatal period alters mesocorticolimbic dopamine in the adult rat offspring: reduction in the behavioral responses to repeated amphetamine administration. *Psychopharmacology*. 2008;197:83–94.
137. Vucetic Z, Kimmel J, Totoki K, Hollenbeck E, Reyes TM. Maternal high-fat diet alters methylation and gene expression of dopamine and opioid-related genes. *Endocrinology*. 2010;151:4756–64.
138. Aguilar-Valles A, Jung S, Poole S, Flores C, Luheshi GN. Leptin and interleukin-6 alter the function of mesolimbic dopamine neurons in a rodent model of prenatal inflammation. *Psychoneuroendocrinology*. 2012;37:956–69.
139. Angelucci F, Brene S, Mathe A. BDNF in schizophrenia, depression and corresponding animal models. *Mol Psychiatry*. 2005;10:345.
140. Vallianou N, Stratigou T, Christodoulatos GS, Dalamaga M. Understanding the role of the gut microbiome and microbial metabolites in obesity and obesity-associated metabolic disorders: current evidence and perspectives. *Curr Obes Rep*. 2019;8:317–32.
141. Sharon G, Cruz NJ, Kang D-W, Gandal MJ, Wang B, Kim Y-M, et al. Human gut microbiota from autism spectrum disorder promote behavioral symptoms in mice. *Cell*. 2019;177:1600–18. e17.
142. Kelly JR, Borre Y, O'Brien C, Patterson E, El Aidi S, Deane J, et al. Transferring the blues: depression-associated gut microbiota induces neurobehavioural changes in the rat. *J Psychiatric Res*. 2016;82:109–18.
143. Zheng P, Zeng B, Liu M, Chen J, Pan J, Han Y, et al. The gut microbiome from patients with schizophrenia modulates the glutamate-glutamine-GABA cycle and schizophrenia-relevant behaviors in mice. *Sci Adv*. 2019;5:eaa8317.
144. Dinan TG, Cryan JF. Brain-gut-microbiota axis and mental health. *Psychosomatic Med*. 2017;79:920–6.
145. Braniste V, Al-Asmakh M, Kowal C, Anuar F, Abbaspour A, Toth M, et al. The gut microbiota influences blood-brain barrier permeability in mice. *Sci Transl Med*. 2014;6:263ra158. *the text*
146. Erny D, de Angelis ALH, Jaitin D, Wieghofer P, Staszewski O, David E, et al. Host microbiota constantly control maturation and function of microglia in the CNS. *Nat Neurosci*. 2015;18:965.
147. Yang LL, Millischer V, Rodin S, MacFabe DF, Villaescusa JC, Lavebratt C. Enteric short-chain fatty acids promote proliferation of human neural progenitor cells. *J Neurochem*. 2019:e14928. <https://doi.org/10.1111/jnc.14928>.
148. Kim S, Kim H, Yim YS, Ha S, Atarashi K, Tan TG, et al. Maternal gut bacteria promote neurodevelopmental abnormalities in mouse offspring. *Nature*. 2017;549:528.
149. Hoirisch-Clapauch S, Nardi AE. Autism spectrum disorders: let's talk about glucose? *Transl Psychiatry*. 2019;9:51.
150. Thion MS, Ginhoux F, Garel S. Microglia and early brain development: an intimate journey. *Science*. 2018;362:185–9.

151. Drong A, Lindgren C, McCarthy M. The genetic and epigenetic basis of type 2 diabetes and obesity. *Clin Pharmacol Ther.* 2012;92:707–15.
152. Scott RA, Scott LJ, Mägi R, Marullo L, Gaulton KJ, Kaakinen M, et al. An expanded genome-wide association study of type 2 diabetes in Europeans. *Diabetes.* 2017;66:2888–902.
153. Lu Y, Day FR, Gustafsson S, Buchkovich ML, Na J, Bataille V, et al. New loci for body fat percentage reveal link between adiposity and cardiometabolic disease risk. *Nat Commun.* 2016;7:10495.
154. Shungin D, Winkler TW, Croteau-Chonka DC, Ferreira T, Locke AE, Mägi R, et al. New genetic loci link adipose and insulin biology to body fat distribution. *Nature.* 2015;518:187.
155. Anttila V, Bulik-Sullivan B, Finucane HK, Walters RK, Bras J, Duncan L, et al. Analysis of shared heritability in common disorders of the brain. *Science.* 2018;360:eaap8757.
156. Broder-Fingert S, Brazauskas K, Lindgren K, Iannuzzi D, Van Cleave J. Prevalence of overweight and obesity in a large clinical sample of children with autism. *Acad Pediatrics.* 2014;14:408–14.
157. Khalife N, Kantomaa M, Glover V, Tammelin T, Laitinen J, Ebeling H, et al. Childhood attention-deficit/hyperactivity disorder symptoms are risk factors for obesity and physical inactivity in adolescence. *J Am Acad Child Adolescent Psychiatry.* 2014;53:425–36.
158. Rohde K, Keller M, la Cour Poulsen L, Blüher M, Kovacs P, Böttcher Y. Genetics and epigenetics in obesity. *Metabolism.* 2019;92:37–50.
159. Larder R, Sim MM, Gulati P, Antrobus R, Tung YL, Rimmington D, et al. Obesity-associated gene TMEM18 has a role in the central control of appetite and body weight regulation. *Proc Natl Acad Sci.* 2017;114:9421–6.
160. Milaneschi Y, Simmons WK, van Rossum EF, Penninx BW. Depression and obesity: evidence of shared biological mechanisms. *Mol Psychiatry.* 2019;24:18–33.
161. Masuo K, Katsuya T, Fu Y, Rakugi H, Ogihara T, Tuck ML. β 2-adrenoceptor polymorphisms relate to insulin resistance and sympathetic overactivity as early markers of metabolic disease in nonobese, normotensive individuals. *Am J Hypertens.* 2005;18:1009–14.
162. Masuo K, Katsuya T, Kawaguchi H, Fu Y, Rakugi H, Ogihara T, et al. β 2-adrenoceptor polymorphisms relate to obesity through blunted leptin-mediated sympathetic activation. *Am J Hypertens.* 2006;19:1084–91.
163. Gjesing A, Andersen G, Burgdorf K, Borch-Johnsen KJ, [slash in circle] rgensen T, Hansen T, Pedersen O. Studies of the associations between functional beta2-adrenergic receptor variants and obesity, hypertension and type 2 diabetes in 7,808 white subjects. *Diabetologia.* 2007;50:563–8.
164. Cheslack-Postava K, Fallin M, Avramopoulos D, Connors S, Zimmerman A, Eberhart CG, et al. β 2-Adrenergic receptor gene variants and risk for autism in the AGRE cohort. *Molecular Psychiatry.* 2007;12:283–91.
165. Hu Z, Tylavsky FA, Han JC, Kocak M, Fowke JH, Davis RL, et al. Maternal metabolic factors during pregnancy predict early childhood growth trajectories and obesity risk: the CANDLE Study. *Int J Obesity.* 2019;43:1914–22.
166. Kaseva N, Vääräsmäki M, Sundvall J, Matinelli H-M, Sipola M, Tikkanmäki M, et al. Gestational diabetes but not prepregnancy overweight predicts for cardiometabolic markers in offspring twenty years later. *J Clin Endocrinol Metabol.* 2019;104:2785–95.
167. Velazquez MA, Fleming T, Watkins AJ. Periconceptional environment and the developmental origins of disease. *J Endocrinol.* 2019;242:T33–T49.
168. Bierhaus A, Wolf J, Andrassy M, Rohleder N, Humpert PM, Petrov D, et al. A mechanism converting psychosocial stress into mononuclear cell activation. *Proc Natl Acad Sci.* 2003;100:1920–5.
169. Fall CH, Kumaran K. Metabolic programming in early life in humans. *Philosoph Trans R Soc B.* 2019;374:20180123.
170. Andersen CH, Thomsen PH, Nohr EA, et al. Maternal body mass index before pregnancy as a risk factor for ADHD and autism in children. *Eur Child Adolesc Psy.* 2018;27:139–148.